| Radius Pt Of Alabama Llc | |
|
7270 Gadsden Hwy # 104-108, Trussville, AL 35173-2640 | |
| (659) 444-1193 | |
| (205) 895-6639 |
| Full Name | Radius Pt Of Alabama Llc |
|---|---|
| Type | Facility |
| Speciality | Clinic/center - Physical Therapy |
| Location | 7270 Gadsden Hwy # 104-108, Trussville, Alabama |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124790480 | NPI | - | NPPES |
| Provider Name | William W Serena |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1588627343 PECOS PAC ID: 1951356427 Enrollment ID: I20170801002335 |
News Archive
Codexis, Inc., a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that the United States Patent and Trademark Office (USPTO) has granted Codexis' patent covering the biocatalysts and biocatalytic processes used to make key pharmaceutical intermediates in the synthesis of leading hepatitis-C therapeutics.
The creation of new blood vessels in the body, called "angiogenesis," is usually discussed in connection with healing wounds and tumors. But it's also an ongoing process in the female reproductive tract, where the growth and breaking of blood vessels is a normal part of the menstrual cycle. But abnormal growth of blood vessels can have painful consequences and resultant pathologies.
MAXIMUS, a leading provider of government services worldwide, announced that it has signed a new contract with the Maryland Health Benefit Exchange to operate the Consolidated Service Center, which includes call center, fulfillment and command center services.
New research from the University of Minnesota College of Veterinary Medicine has uncovered the role gene ORMDL3 plays in the disease asthma. ORMDL3, a gene recently linked to asthma susceptibility, has now been linked to the body's ability to recruit inflammatory cells during an airway allergic reaction. Study findings appear today in the journal Nature Communications.
ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.
› Verified 4 days ago
| Provider Name | Kaci Mariah Bemowski |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1447819453 PECOS PAC ID: 8022346378 Enrollment ID: I20190823001684 |
News Archive
Codexis, Inc., a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that the United States Patent and Trademark Office (USPTO) has granted Codexis' patent covering the biocatalysts and biocatalytic processes used to make key pharmaceutical intermediates in the synthesis of leading hepatitis-C therapeutics.
The creation of new blood vessels in the body, called "angiogenesis," is usually discussed in connection with healing wounds and tumors. But it's also an ongoing process in the female reproductive tract, where the growth and breaking of blood vessels is a normal part of the menstrual cycle. But abnormal growth of blood vessels can have painful consequences and resultant pathologies.
MAXIMUS, a leading provider of government services worldwide, announced that it has signed a new contract with the Maryland Health Benefit Exchange to operate the Consolidated Service Center, which includes call center, fulfillment and command center services.
New research from the University of Minnesota College of Veterinary Medicine has uncovered the role gene ORMDL3 plays in the disease asthma. ORMDL3, a gene recently linked to asthma susceptibility, has now been linked to the body's ability to recruit inflammatory cells during an airway allergic reaction. Study findings appear today in the journal Nature Communications.
ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.
› Verified 4 days ago
| Provider Name | Joseph Reece Bemowski |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1831744127 PECOS PAC ID: 5698004091 Enrollment ID: I20190910003851 |
News Archive
Codexis, Inc., a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that the United States Patent and Trademark Office (USPTO) has granted Codexis' patent covering the biocatalysts and biocatalytic processes used to make key pharmaceutical intermediates in the synthesis of leading hepatitis-C therapeutics.
The creation of new blood vessels in the body, called "angiogenesis," is usually discussed in connection with healing wounds and tumors. But it's also an ongoing process in the female reproductive tract, where the growth and breaking of blood vessels is a normal part of the menstrual cycle. But abnormal growth of blood vessels can have painful consequences and resultant pathologies.
MAXIMUS, a leading provider of government services worldwide, announced that it has signed a new contract with the Maryland Health Benefit Exchange to operate the Consolidated Service Center, which includes call center, fulfillment and command center services.
New research from the University of Minnesota College of Veterinary Medicine has uncovered the role gene ORMDL3 plays in the disease asthma. ORMDL3, a gene recently linked to asthma susceptibility, has now been linked to the body's ability to recruit inflammatory cells during an airway allergic reaction. Study findings appear today in the journal Nature Communications.
ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.
› Verified 4 days ago
| Provider Name | Shannon Wolverton |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1417303249 PECOS PAC ID: 9739471327 Enrollment ID: I20211215002318 |
News Archive
Codexis, Inc., a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that the United States Patent and Trademark Office (USPTO) has granted Codexis' patent covering the biocatalysts and biocatalytic processes used to make key pharmaceutical intermediates in the synthesis of leading hepatitis-C therapeutics.
The creation of new blood vessels in the body, called "angiogenesis," is usually discussed in connection with healing wounds and tumors. But it's also an ongoing process in the female reproductive tract, where the growth and breaking of blood vessels is a normal part of the menstrual cycle. But abnormal growth of blood vessels can have painful consequences and resultant pathologies.
MAXIMUS, a leading provider of government services worldwide, announced that it has signed a new contract with the Maryland Health Benefit Exchange to operate the Consolidated Service Center, which includes call center, fulfillment and command center services.
New research from the University of Minnesota College of Veterinary Medicine has uncovered the role gene ORMDL3 plays in the disease asthma. ORMDL3, a gene recently linked to asthma susceptibility, has now been linked to the body's ability to recruit inflammatory cells during an airway allergic reaction. Study findings appear today in the journal Nature Communications.
ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.
› Verified 4 days ago
| Provider Name | Nicholas J Stanton |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1962154625 PECOS PAC ID: 5193110674 Enrollment ID: I20220318002377 |
News Archive
Codexis, Inc., a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that the United States Patent and Trademark Office (USPTO) has granted Codexis' patent covering the biocatalysts and biocatalytic processes used to make key pharmaceutical intermediates in the synthesis of leading hepatitis-C therapeutics.
The creation of new blood vessels in the body, called "angiogenesis," is usually discussed in connection with healing wounds and tumors. But it's also an ongoing process in the female reproductive tract, where the growth and breaking of blood vessels is a normal part of the menstrual cycle. But abnormal growth of blood vessels can have painful consequences and resultant pathologies.
MAXIMUS, a leading provider of government services worldwide, announced that it has signed a new contract with the Maryland Health Benefit Exchange to operate the Consolidated Service Center, which includes call center, fulfillment and command center services.
New research from the University of Minnesota College of Veterinary Medicine has uncovered the role gene ORMDL3 plays in the disease asthma. ORMDL3, a gene recently linked to asthma susceptibility, has now been linked to the body's ability to recruit inflammatory cells during an airway allergic reaction. Study findings appear today in the journal Nature Communications.
ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.
› Verified 4 days ago
| Provider Name | Ana Steidinger |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1750156261 PECOS PAC ID: 6406206317 Enrollment ID: I20231219000607 |
News Archive
Codexis, Inc., a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that the United States Patent and Trademark Office (USPTO) has granted Codexis' patent covering the biocatalysts and biocatalytic processes used to make key pharmaceutical intermediates in the synthesis of leading hepatitis-C therapeutics.
The creation of new blood vessels in the body, called "angiogenesis," is usually discussed in connection with healing wounds and tumors. But it's also an ongoing process in the female reproductive tract, where the growth and breaking of blood vessels is a normal part of the menstrual cycle. But abnormal growth of blood vessels can have painful consequences and resultant pathologies.
MAXIMUS, a leading provider of government services worldwide, announced that it has signed a new contract with the Maryland Health Benefit Exchange to operate the Consolidated Service Center, which includes call center, fulfillment and command center services.
New research from the University of Minnesota College of Veterinary Medicine has uncovered the role gene ORMDL3 plays in the disease asthma. ORMDL3, a gene recently linked to asthma susceptibility, has now been linked to the body's ability to recruit inflammatory cells during an airway allergic reaction. Study findings appear today in the journal Nature Communications.
ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Radius Pt Of Alabama Llc 7270 Gadsden Hwy # 104-108, Trussville, AL 35173-2640 Ph: (659) 444-1193 | Radius Pt Of Alabama Llc 7270 Gadsden Hwy # 104-108, Trussville, AL 35173-2640 Ph: (659) 444-1193 |
News Archive
Codexis, Inc., a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that the United States Patent and Trademark Office (USPTO) has granted Codexis' patent covering the biocatalysts and biocatalytic processes used to make key pharmaceutical intermediates in the synthesis of leading hepatitis-C therapeutics.
The creation of new blood vessels in the body, called "angiogenesis," is usually discussed in connection with healing wounds and tumors. But it's also an ongoing process in the female reproductive tract, where the growth and breaking of blood vessels is a normal part of the menstrual cycle. But abnormal growth of blood vessels can have painful consequences and resultant pathologies.
MAXIMUS, a leading provider of government services worldwide, announced that it has signed a new contract with the Maryland Health Benefit Exchange to operate the Consolidated Service Center, which includes call center, fulfillment and command center services.
New research from the University of Minnesota College of Veterinary Medicine has uncovered the role gene ORMDL3 plays in the disease asthma. ORMDL3, a gene recently linked to asthma susceptibility, has now been linked to the body's ability to recruit inflammatory cells during an airway allergic reaction. Study findings appear today in the journal Nature Communications.
ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.
› Verified 4 days ago